<DOC>
	<DOCNO>NCT00024089</DOCNO>
	<brief_summary>Phase II trial study effectiveness gefitinib treat patient recurrent and/or metastatic head neck cancer . Biological therapy gefitinib may interfere growth tumor cell block enzyme necessary cell growth .</brief_summary>
	<brief_title>Gefitinib Treating Patients With Recurrent and/or Metastatic Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine disease control rate , term complete response , partial response , stable disease least 4 month , patient recurrent and/or metastatic squamous cell cancer head neck treat gefitinib . II . Determine effect drug epidermal growth factor receptor phosphorylation expression select gene patient . III . Determine toxic effect drug patient . OUTLINE : Patients stratify delineated Disease Characteristics . Patients receive oral gefitinib daily . Treatment repeat every 28 day absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm primary squamous cell cancer head neck incurable surgery radiotherapy Stratum I : Failed surgery and/or radiotherapy receive prior systemic chemotherapy recurrent disease OR Recurrent disease least 6 month prior multimodal primary therapy include neoadjuvant concurrent chemotherapy OR Metastatic disease initial diagnosis receive prior chemotherapy Stratum II : No 1 prior chemotherapy regimen recurrent disease OR Recurrent disease within 6 month prior primary therapy include chemotherapy Measurable disease At least 20 mm conventional technique OR least 10 mm spiral CT scan Clear clinical evidence progression biopsyproven residual cancer require site measurable disease previously irradiate field No known brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 OR Karnofsky 60100 % Life expectancy : More 3 month Hematopoietic : WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin normal ( great 1.5 time upper limit normal [ ULN ] liver metastasis present ) AST/ALT great 2.5 time ULN Renal : Creatinine great 1.5 time ULN OR Creatinine clearance least 60 mL/min Cardiovascular : No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other : No malignancy within past 5 year except curatively treat basal cell squamous cell skin cancer carcinoma situ cervix No uncontrolled concurrent illness No ongoing active infection No psychiatric illness social situation would preclude study compliance No prior allergic reaction attribute compound similar chemical biologic composition gefitinib Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior therapy agent target epidermal growth factor receptor Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Endocrine therapy : No concurrent tamoxifen Radiotherapy : Prior radiotherapy primary secondary treatment allow At least 4 week since prior radiotherapy recover Surgery : Prior surgery primary secondary treatment allow At least 4 week since prior major surgery Other : No concurrent investigational agent No concurrent combination antiretroviral therapy HIV No concurrent 3A4 inhibitor ( e.g. , ketoconazole , erythromycin , verapamil ) No concurrent drug know corneal toxicity ( e.g. , chlorpromazine , amiodarone , chloroquine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2005</verification_date>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>metastatic squamous neck cancer occult primary squamous cell carcinoma</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>salivary gland squamous cell carcinoma</keyword>
</DOC>